Pascal Furet

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Total Synthesis and Biological Evaluation of the Nakijiquinones

Petra Stahl, Lars Kissau, Ralph Mazitschek et al. · Journal of the American Chemical Society · 2001 · 113 citations

Crystal Structure, Medicinal Chemistry, Bioorganic Chemistry +13

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 104 citations · Full text

Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives

Peter Bühlmayer, Leoluca Criscione, Walter Fuhrer et al. · Journal of Medicinal Chemistry · 1991 · 36 citations · Full text

New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives

Olivier Lohse, Ulrich Beutler, Peter C. Fünfschilling et al. · Tetrahedron Letters · 2001 · 35 citations

Medicinal Chemistry, Natural Sciences, Protected N-o-tolyl-anthranilamide Derivatives +8